

**Medicaid Drug Utilization Review Board  
Meeting Agenda  
October 20, 2011**

The Drug Utilization Review (DUR) Board will meet on October 20, 2011, from 9:00 a.m. to 4:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

**Agenda Items**

**A. Drug Utilization Review**

1. Methadone/Methadose
2. Quetiapine (Seroquel IR, Seroquel XR)
3. Fentanyl - (Duragesic, Actiq, Fentora, Onsolis, Abstral)
4. Hepatitis C virus (HVC) Protease Inhibitors-  
Drugs: boceprevir (Victrelis), telaprevir (Incivek)
5. Morphine and Congeners-  
Drugs: Avinza, butalbital compound w/codeine, codeine, codeine/APAP dihydrocodeine/APAP/caffeine, Dilaudid, Endocet, Endodan, Exalgo, Hycet, hydrocodone/APAP, hydrocodone/ibuprofen, hydromorphone, Ibudone, Kadian, Lorcet, Lorcet Plus, Lortab, Magnacet, Margesic H, Maxidone, morphine sulfate, morphine sulfate SR, MS Contin, Norco, Opana, Opana ER, Oramorph SR, oxycodone, oxycodone/APAP, oxycodone/ASA, oxycodone/ibuprofen, oxymorphone, OxyIR, Panlor SS, Percocet, Percodan, Primlev, Reprexain, Roxicet , Roxicodone, Synalgos DC, Trezix, Tylenol w/codeine no.3, Tylenol w/codeine no.4, Tylox, Vicodin, Vicodin ES, Vicodin HP, Vicoprofen, Xodol, Xolox, Zamicet, Zydone
6. Tesamorelin (Egrifta)

**B. Program Updates**

- Prescriber Education Program
- PSYCKES
- Medicaid Pharmacy Program/MRT Initiatives

**Agenda Timeline** (subject to change based on meeting proceedings)

9:00 - 9:15	Welcome and Introductions
9:15 - 10:15	Public Comment Period*
10:15 - 10:30	Prescriber Education Program
10:30 - 12:30	Drug Utilization Review
12:30 - 1:30	Lunch (Executive Session)

1:30 - 2:00	PSYCKES
2:00 - 3:30	Drug Utilization Review (continued)
3:30 – 4:00	Medicaid Pharmacy Program/MRT Initiatives
4:00	Comments/Adjournment

\*Interested parties must notify DOH at least one (1) week prior to the meeting of their request to address the DUR Board during the public comment period. Requests may be made by phone (518-486-3209) or e-mail ([DUR@health.state.ny.us](mailto:DUR@health.state.ny.us)). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes.

All written statements must be received in an electronic format ([DUR@health.state.ny.us](mailto:DUR@health.state.ny.us)) up to one (1) week in advance of the meeting. Written statements should summarize key points and may not exceed two (2) pages in length. If the submission of clinical information greater than two (2) pages in length is needed, the information must be received at least two (2) weeks prior to the meeting date or the Board may not have ample time to review the information. Please contact Department of Health (DOH) staff by e-mail ([DUR@health.state.ny.us](mailto:DUR@health.state.ny.us)) prior to sending any information greater than two (2) pages.

Note: All information must be submitted to the DOH. Information should not be submitted directly to DUR Board members. DOH will ensure all information received (according to the guidelines above) is available for DUR Board review prior to the meeting.

Posted 09/21/2011